نتایج جستجو برای: pneumococcal conjugate vaccine

تعداد نتایج: 152834  

2016
Sarocha Chootipongchaivat Varit Chantarastapornchit Wantanee Kulpeng Joyce Anne Ceria Niña Isabelle Tolentino Yot Teerawattananon

OBJECTIVE Implementing national-level vaccination programs involves long-term investment, which can be a significant financial burden, particularly in resource-limited settings. Although many studies have assessed the economic impacts of providing vaccinations, evidence on the positive and negative implications of human resources for health (HRH) is still lacking. Therefore, this study aims to ...

2011
Yoon Hong Choi Mark Jit Nigel Gay Nick Andrews Pauline A. Waight Alessia Melegaro Robert George Elizabeth Miller

BACKGROUND The UK introduced the 7-valent pneumococcal conjugate vaccine (PCV7) into the national vaccination program in September 2006. Previous modelling assumed that the likely impact of PCV7 on invasive pneumococcal disease (IPD) would be similar to the US experience with PCV7. However, recent surveillance data show a more rapid replacement of PCV7 IPD cases by non-PCV7 IPD cases than was s...

2017
Jordi Càmara José María Marimón Emilia Cercenado Nieves Larrosa María Dolores Quesada Dionísia Fontanals Meritxell Cubero Emilio Pérez-Trallero Asunción Fenoll Josefina Liñares Carmen Ardanuy

A prospective laboratory-based multicenter study that collected all adult invasive pneumococcal disease (IPD) episodes from 6 Spanish hospitals before (2008-2009) and after (2012-2013). The 13-valent pneumococcal conjugate vaccine (PCV13) licensure was conducted in order to analyze the impact of PCV13 introduction for children on adult IPD. A total of 1558 IPD episodes were detected. The incide...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011
Jennifer B Rosen Ann R Thomas Catherine A Lexau Art Reingold Jim L Hadler Lee H Harrison Nancy M Bennett William Schaffner Monica M Farley Bernard W Beall Matt R Moore

BACKGROUND Rates of invasive pneumococcal disease (IPD) varied among the United States before pneumococcal conjugate vaccine (PCV7) introduction. We compared trends in IPD rates among diverse US sites over 10 years since PCV7 introduction. METHODS Patients with IPD of all ages were identified through active population and laboratory-based surveillance in 8 geographic areas under continuous su...

Journal: :Vaccine 2010
Norberto D Giglio Alejandro D Cane Paula Micone Angela Gentile

UNLABELLED Due to the region's own conditions, universal vaccination with pneumococcal conjugate heptavalent vaccine (PCV-7) in Latin American countries is still controversial. OBJECTIVE To compare projected economic costs and health benefits associated with pneumococcal conjugate heptavalent vaccine as a routine immunization in healthy children in Argentina. DESIGN A decision analytic mode...

Journal: :The Journal of infectious diseases 2007
Marc Lipsitch Keith O'Neill Derrick Cordy Boris Bugalter Krzysztof Trzcinski Claudette M Thompson Richard Goldstein Stephen Pelton Heather Huot Valerie Bouchet Raymond Reid Mathuram Santosham Katherine L O'Brien

Widespread use of 7-valent pneumococcal conjugate vaccine (PCV7) has led to significant reductions in disease while changing pneumococcal population dynamics via herd immunity and serotype replacement. We performed multilocus sequence typing (MLST) on 590 pneumococcal isolates obtained during the American Indian clinical trial of PCV7, in which communities were randomized for eligible children ...

2013
Young June Choe Eun Hwa Choi Hoan Jong Lee

The wide use of antimicrobial agents and 7-valent pneumococcal conjugate vaccine (PCV7) has led to major changes in the epidemiology of childhood pneumococcal diseases. In Korea, data on the population-based incidence of childhood invasive pneumococcal diseases (IPD) are not available; however, institution-based surveillance data suggest a substantial burden of childhood IPD. Following the intr...

2015
Raul Isturiz Chris Webber

The aging of the world population is expected to be accompanied by increased pneumococcal pneumonia in older adults. To address this, the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA), a large, randomized, placebo-controlled trial conducted to assess the 13-valent pneumococcal conjugate vaccine (PCV13) in adults ≥ 65 years, found statistically significant vaccine efficacy f...

Journal: :The Lancet. Infectious diseases 2015
Matthew R Moore Ruth Link-Gelles William Schaffner Ruth Lynfield Catherine Lexau Nancy M Bennett Susan Petit Shelley M Zansky Lee H Harrison Arthur Reingold Lisa Miller Karen Scherzinger Ann Thomas Monica M Farley Elizabeth R Zell Thomas H Taylor Tracy Pondo Loren Rodgers Lesley McGee Bernard Beall James H Jorgensen Cynthia G Whitney

BACKGROUND In 2000, seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and moderate increases in non-PCV7 type IPD. In 2010, PCV13 replaced PCV7 in the US immunisation schedule. We aimed to assess the effect of use of PCV13 in children on IPD in children and adults in the USA. METHODS We used ...

2017
Joshua L Warren Kayoko Shioda Esra Kürüm Cynthia Schuck-Paim Roger Lustig Robert J Taylor Lone Simonsen Daniel M Weinberger

Background Pneumococcal conjugate vaccines (PCVs) are being used worldwide. A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income populations. However, most low-income countries, where the burden of disease is greatest, lack reliable data that can be used to evaluate the impact. Data from middle-income countries that have both low- and high-income subpopul...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید